1 week Ago By ABMN Staff
D. Boral Capital started coverage on shares of Omeros ( NASDAQ:OMER – Free Report ) in a research note published on Monday, MarketBeat reports. The firm issued a buy rating and a $36.
00 price objective on the biopharmaceutical company’s stock. A number of other analysts also recently weighed in on OMER. Cantor Fitzgerald restated a “neutral” rating on shares of Omeros in a report on Thursday, November 14th.
StockNews.com raised Omeros from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th. Needham & Company LLC reaffirmed a “hold” rating on shares of Omeros in a research note on Thursday, December 19th.
RODMAN&RENSHAW upgraded Omeros to a “strong-buy” rating in a report on Thursday, November 14th. Finally, Rodman & Renshaw initiated coverage on shares of Omeros in a report on Thursday, November 14th. They set a “buy” rating and a $9.
00 price target for the company. Three research analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $22.
50. Read Our Latest Analysis on Omeros Omeros Price Performance Institutional Inflows and Outflows A number of hedge funds and other institutional investors have recently made changes to their positions in OMER. Barclays PLC increased its holdings in Omeros by 121.
3% in the third quarter. Barclays PLC now owns 94,640 shares of the biopharmaceutical company’s stock worth $376,000 after purchasing an additional 51,873 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Omeros by 0.
5% during the 3rd quarter. Geode Capital Management LLC now owns 1,339,251 shares of the biopharmaceutical company’s stock worth $5,318,000 after buying an additional 6,839 shares during the period. MML Investors Services LLC grew its position in shares of Omeros by 19.
2% during the 3rd quarter. MML Investors Services LLC now owns 18,600 shares of the biopharmaceutical company’s stock worth $74,000 after buying an additional 3,000 shares during the period. Jane Street Group LLC increased its stake in shares of Omeros by 15.
9% in the 3rd quarter. Jane Street Group LLC now owns 58,277 shares of the biopharmaceutical company’s stock valued at $231,000 after acquiring an additional 8,010 shares in the last quarter. Finally, Wellington Management Group LLP acquired a new position in shares of Omeros during the 3rd quarter valued at $305,000.
48.79% of the stock is owned by institutional investors and hedge funds. About Omeros ( Get Free Report ) Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders.
The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. Featured Stories Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter .
.
